Advanced Glycation End products in Children with Obesity and Children with Diabetes Mellitus type 1

Advanced Glycation End products in Children with Obesity and Children with Diabetes Mellitus type 1 - GLYCOD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40284

Enrollment

300

Registered

2013-09-17

Start date

2013-09-23

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesitas Advanced Glycation End products. glycated proteins

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: -

Exclusion criteria

Exclusion criteria: -A dark-colored skin with a reflectance below 12%, measured with the AGE Reader. -Use of sun protection cream up to 5 days or self tanner up to 14 days before examination.

Design outcomes

Primary

Measure	Time frame
the level of sAF in children and young adults with T1DM and in children with obesity with or without T2DM and the correlation between sAF levels and HbA1c in children and young adults with T1DM and in children with obesity with or without T2DM.	—

Secondary

Measure	Time frame
correlation between sAF levels and age. correlation between sAF levels and body mass index (BMI). correlation between sAF levels and duration of T1DM correlation between sAF levels and duration of obesity (if traceable). correlation between sAF levels and duration of T2DM. correlation between sAF levels and cardiovascular parameters correlation between sAF levels and lipid profile. correlation between sAF levels and renal function. correlation between sAF levels and use of medication for co-morbidities. correlation between sAF levels and fasting plasma glucose (FPG). correlation between sAF levels and fasting plasma insulin (FPI). correlation between sAF levels and insulin resistance (IR). correlation between sAF levels and impaired glucose tolerance (IGT).	—

Measure

Time frame

correlation between sAF levels and age. correlation between sAF levels and body mass index (BMI). correlation between sAF levels and duration of T1DM correlation between sAF levels and duration of obesity (if traceable). correlation between sAF levels and duration of T2DM. correlation between sAF levels and cardiovascular parameters correlation between sAF levels and lipid profile. correlation between sAF levels and renal function. correlation between sAF levels and use of medication for co-morbidities. correlation between sAF levels and fasting plasma glucose (FPG). correlation between sAF levels and fasting plasma insulin (FPI). correlation between sAF levels and insulin resistance (IR). correlation between sAF levels and impaired glucose tolerance (IGT).

—

Countries

Netherlands

Outcome results